Mostra i principali dati dell'item
Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives
dc.creator | Kottorou A., Dimitrakopoulos F.-I., Tsezou A. | en |
dc.date.accessioned | 2023-01-31T08:45:03Z | |
dc.date.available | 2023-01-31T08:45:03Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.tranon.2021.101101 | |
dc.identifier.issn | 19365233 | |
dc.identifier.uri | http://hdl.handle.net/11615/75251 | |
dc.description.abstract | Cachexia is a multifactorial syndrome characterized by skeletal muscle loss, with or without adipose atrophy, irreversible through nutritional support, in the context of systemic inflammation and metabolic disorders. It is mediated by inflammatory reaction and affects almost 50% of all cancer patients, due to prominent systemic inflammation associated with the disease. The comprehension of the molecular mechanisms that are implicated in cancer cachexia sheds light on its pathogenesis and lays the foundations for the discovery of new therapeutic targets and biomarkers. Recently, ncRNAs, like microRNAs as well as lncRNAs and circRNAs seem to regulate pathways that are implicated in cancer cachexia pathogenesis, as it has been observed in animal models and in cancer cachexia patients, highlighting their therapeutic potential. Moreover, increasing evidence highlights the involvement of circulating and exosomal ncRNAs in the activation and maintenance of systemic inflammation in cancer and cancer-associated cachexia. In that context, the present review focuses on the clinical significance of ncRNAs in cancer-associated cachexia. © 2021 | en |
dc.language.iso | en | en |
dc.source | Translational Oncology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106548838&doi=10.1016%2fj.tranon.2021.101101&partnerID=40&md5=3cc0d50a98433f2946f09b76162d6980 | |
dc.subject | biological marker | en |
dc.subject | interleukin 6 | en |
dc.subject | leptin | en |
dc.subject | long untranslated RNA | en |
dc.subject | microRNA | en |
dc.subject | myosin heavy chain | en |
dc.subject | myostatin | en |
dc.subject | peroxisome proliferator activated receptor gamma | en |
dc.subject | polycomb repressive complex 2 | en |
dc.subject | prostaglandin E2 | en |
dc.subject | protein p53 | en |
dc.subject | sirtuin 1 | en |
dc.subject | toll like receptor 7 | en |
dc.subject | transcriptome | en |
dc.subject | transthyretin | en |
dc.subject | uncoupling protein 3 | en |
dc.subject | untranslated RNA | en |
dc.subject | astrocytoma | en |
dc.subject | cachexia | en |
dc.subject | carcinogenesis | en |
dc.subject | chronic myeloid leukemia | en |
dc.subject | clinical outcome | en |
dc.subject | cystectomy | en |
dc.subject | cytokine production | en |
dc.subject | disease free survival | en |
dc.subject | DNA methylation | en |
dc.subject | DNA sequence | en |
dc.subject | down regulation | en |
dc.subject | epithelial mesenchymal transition | en |
dc.subject | exosome | en |
dc.subject | fat mass | en |
dc.subject | gene control | en |
dc.subject | gene expression | en |
dc.subject | gene silencing | en |
dc.subject | gene therapy | en |
dc.subject | genetic transfection | en |
dc.subject | head and neck cancer | en |
dc.subject | high throughput sequencing | en |
dc.subject | human | en |
dc.subject | hypercalcemia | en |
dc.subject | immune response | en |
dc.subject | insulin resistance | en |
dc.subject | Lewis carcinoma | en |
dc.subject | lung adenocarcinoma | en |
dc.subject | mesenchymal stem cell | en |
dc.subject | metastasis | en |
dc.subject | muscle atrophy | en |
dc.subject | muscle growth | en |
dc.subject | muscle hypertrophy | en |
dc.subject | muscle mass | en |
dc.subject | muscle regeneration | en |
dc.subject | muscle strength | en |
dc.subject | muscular dystrophy | en |
dc.subject | nuclear reprogramming | en |
dc.subject | osteosarcoma | en |
dc.subject | overall survival | en |
dc.subject | peroperative complication | en |
dc.subject | quality of life | en |
dc.subject | rectus abdominis muscle | en |
dc.subject | resistance training | en |
dc.subject | Review | en |
dc.subject | RNA editing | en |
dc.subject | sarcopenia | en |
dc.subject | signal transduction | en |
dc.subject | skeletal muscle | en |
dc.subject | spinal muscular atrophy | en |
dc.subject | tumor growth | en |
dc.subject | upregulation | en |
dc.subject | Neoplasia Press, Inc. | en |
dc.title | Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives | en |
dc.type | other | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |